83,437 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 83,437 shares of the company’s stock, valued at approximately $185,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Blair William & Co. IL grew its stake in Cardiff Oncology by 32.2% in the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock valued at $505,000 after acquiring an additional 55,450 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Cardiff Oncology by 82.9% in the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock worth $350,000 after purchasing an additional 71,390 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Cardiff Oncology by 34.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock valued at $42,000 after purchasing an additional 4,892 shares during the period. Thoroughbred Financial Services LLC bought a new stake in Cardiff Oncology during the 2nd quarter valued at $116,000. Finally, American Century Companies Inc. increased its stake in Cardiff Oncology by 98.7% during the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after purchasing an additional 22,536 shares in the last quarter. 16.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Craig Hallum began coverage on shares of Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 target price on the stock.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $2.67 on Tuesday. Cardiff Oncology, Inc. has a 52-week low of $0.94 and a 52-week high of $6.42. The company has a 50-day simple moving average of $2.37 and a two-hundred day simple moving average of $3.22. The company has a market capitalization of $124.29 million, a price-to-earnings ratio of -2.97 and a beta of 1.95.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. During the same period in the prior year, the business earned ($0.25) earnings per share. On average, sell-side analysts forecast that Cardiff Oncology, Inc. will post -1 EPS for the current fiscal year.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.